Venous thromboembolism in women using hormonal contraceptives: Findings from the RIETE registry

Thrombosis and Haemostasis

Volumn 101, Issue 3, 2009, Pages 478-482

  Ángeles, Bianco Molina ^a   Javier, Trujillo Santos ^b   Tirado, Raimundo ^c   Cañas, Inmaculada ^d   Riera, Antoni ^e   Valdés, Mariano ^f   Monreal, Manuel ^g  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Hospital Universitario Santa María de Resell   (Spain)

^c HOSPITAL INFANTA MARGARITA   (Spain)

^d HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL DE VILADECANS   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Contraceptives; Prevention; Venous thromboembolism

Indexed keywords

CONTRACEPTIVE AGENT; CYPROTERONE; DESOGESTREL; DROSPIRENONE; GESTODENE; LEVONORGESTREL; LOW MOLECULAR WEIGHT HEPARIN; MEDROXYPROGESTERONE; NORGESTIMATE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMOBILIZATION; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; THROMBOPHILIA; VAGINA RING; VENOUS THROMBOEMBOLISM;

ADULT; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; MIDDLE AGED; PREGNANCY; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 62549115738     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-10-0684     Document Type: Article

References (21)

1. Sidney S, Petitti DB, Soff GA, et al. Venous thromboembolic disease in users of low-estrogen combined eslrogen-progestin oral contraceptives. Contraception 2004;70: 3-10.
2. WHO. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific group. WHO Technical Report Series 877. Geneva: WHO 1998: pp. 1-89.
3. Battaglioli T, Martinelli I. Hormone therapy and thromboembolic disease. Curr Opin Hematol 2007; 14: 488-493.
4. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thromboembolism: meta-analysis. Br Med J 2001; 323: 131-134.
5. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187-196.
6. Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. A clinical review. Arch Intern Med 2004; 164: 1965-1976.
7. Cushman M, Glynn RJ, Goldhaber SZ, et al. Hormonal factors and risk of recurrent venous thrombosis: the Prevention of Recurrent Venous Thromboembolism trial. J Thromb Haemost 2006; 4: 2199-2203.
8. Cole JA, Norman II, Doherty M, et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109: 339-346.
9. Abdollahi M. Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-498.
10. Pomp ER, le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis : obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
11. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Br Med J 2008; 336: 1227-1231.
12. Monreal M, Falgá C, Valle R, et al, for the RIETE Investigators. Venous thromboembolism in patients with renal insufficiency. Findings from the RIETE Registry. Am J Med 2006; 119: 1073-1079.
13. Falgà C, Capdevila JA, Soler S, et al., for the RIETE Investigators. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE Registry. Thromb Haemost 2007; 98: 771-776.
14. Bianco-Molina A, Trujillo-Santos J, Criado J. et al., and the RIETE Investigators. Venous thrombo-embolism during pregnancy or postpartum: Findings from the RIETE Registry. Thromb Haemost 2007; 97: 186-190.
15. Ruiz-Giménez N, Suárez C, González R, et al., and the RIETE Investigators. Predictive variables for major bleeding in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31.
16. Laporte S, Mismetti P, Décousus H, et al. and the RIETE investigators. Predictive factors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism. Findings from the RIETE registry. Circulation 2008; 117: 1711-1716.
17. ACOG Practice Bulletin N 73. Use of hormonal contraception in women with coexisting medical conditions Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2006; 107: 1453-1472.
18. Bloemenkamp KWM, Rosendaal FR, Helmersorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49-52.
19. Scarabin P-Y. Oger E, Plu-Bureau G, for the ESTHER study group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432.
20. th Edition). Chest 2008; 133: 381s-453s.
21. ACOG Practice Bulletin N 73. Use of hormonal contraception in women with coexisting medical conditions Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2006; 107: 1453-1472.